ERRATUM

Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients

Laurent Vroonen, Marie-Lise Jaffrain-Rea, Patrick Petrossians, Gianluca Tamagno, Philippe Chanson, Lucio Vilar, Françoise Borson-Chazot, Luciana A Naves, Thierry Brue, Blandine Gatta, Brigitte Delemer, Enrica Ciccarelli, Paolo Beck-Peccoz, Philippe Caron, Adrian F Daly and Albert Beckers

The journal apologises for an error in the footnote to table 3 of this article published in the November issue of the *European Journal of Endocrinology* (vol **167**, iss 5, pp 651–662). In the footnote, the information relating to the clinical details of patients should read as:

^aClinical details on patients 1 and 3 have been reported in references (40, 42) respectively.

and not as published

European Journal of Endocrinology **167** 887

References

- 40 Petrossians P, de Herder W, Kwekkeboom D, Lamberigts G, Stevenaert A & Beckers A. Malignant prolactinoma discovered by D2 receptor imaging. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 398–401. (doi:10.1210/jc.85.1.398)
- 42 Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F & Brue T. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. *Journal of Clinical Endocrinology and Metabolism* 2010 **95** 4592–4599. (doi:10.1210/jc.2010-0644)